Harrow (HROW) Investor Day 2025 summary

Strategic Vision and Business Model

• Aims to become the leading U.S. ophthalmic company, leveraging a founder-led, entrepreneurial approach and disciplined M&A to build the largest, most diversified ophthalmic portfolio in North America.

• Focuses on sustainable, profitable growth through targeted acquisitions, efficient integration, and a scalable commercial platform.

• Maintains a merit-based culture, aligning leadership and staff incentives with shareholder value.

• Recent refinancing improved liquidity, lowered cost of capital, and extended debt maturity, supporting future growth and BD opportunities.

• Commercial teams are organized by therapeutic area, with programs ensuring patient access for as low as $0 or a maximum of $59.

Financial Guidance and Growth Outlook

• 2025 revenue guidance set at over $280 million, with expectations for stronger second-half performance and 40% growth compared to 2024.

• Targets $250 million+ in quarterly revenue by Q4 2027, driven by VEVYE, retina portfolio (IHEEZO, TRIESENCE, biosimilars), and new launches.

• Gross margins expected in the low to mid-80% range, with operating margins of 30%-40% at target revenue levels.

• Maintains leverage targets under 3x gross and 2x net, with strong historical growth exceeding 40% annually (except 2021).

• Maintains a stable operating cost structure with scalable commercial platforms.

Pipeline and Product Development

• Pipeline strategy emphasizes de-risked, capital-efficient development, with both organic and partnered assets.

• Key upcoming launches: MELT-300 (NDA filing 2027, launch 2028), TRIESENCE prefilled syringe (NDA by end of 2027, launch 2028), and a conjunctival delivery device for rare ocular neoplasia (potential launch 2029).

• MELT-300 demonstrated statistical superiority over midazolam and placebo in Phase 3, with a favorable safety profile and broad label expansion potential.

• FDA Special Protocol Assessment agreement in place for MELT-300, with anticipated approval and launch timelines.

• TRIESENCE prefilled syringe to enhance usability and manufacturing robustness, maintaining broad indications.